1703 GMT - Big European pharmaceutical stocks have rallied in recent weeks, which makes them vulnerable should companies' 2026 guidance disappoint, Bank of America analysts say in a note. The likely outlooks from AstraZeneca and Novartis look safe relative to consensus expectations, Bank of America says. Meanwhile, there could be some risk that the outlooks issued by GSK, Novo Nordisk and Sanofi fall short of forecasts, according to Bank of America. For Roche, Bank of America expects guidance of sales growth in the mid-single-digit percentage range excluding currency movements and earnings per share growth of high single digits, broadly in line with consensus, but sees room for a more cautious view. The Stoxx Europe 600 Health Care index closes 0.6% higher, and is up 7.25% over the past month. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

January 16, 2026 12:03 ET (17:03 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.